EX-99
7
exh99_1.txt
EXH 99.1 - PRESS RELEASE - SEPT. 7, 2005
EXHIBIT 99.1
JAVELIN
FOR IMMEDIATE RELEASE
INTRAC CHANGES NAME TO JAVELIN PHARMACEUTICALS
New York, NY, September 7, 2005 - Today at its annual meeting of shareholders,
INTRAC, INC. (OTC BB: ITRD) changed its name to Javelin Pharmaceuticals, Inc. as
part of a reincorporation in the State of Delaware. Javelin common stock will
trade under the symbol JVPH on the OTC Bulletin Board. The shareholders also
elected the management slate of directors and ratified the Omnibus Stock
Incentive Plan.
This renaming reflects the array of pain management opportunities that the
Company plans to pursue as it expands beyond its present boundaries. The new
name took effect after receiving shareholder approval and completing regulatory
filings. Intrac's wholly owned subsidiary, Innovative Drug Delivery Systems,
Inc., is now a wholly owned subsidiary of Javelin.
"This important strategic step reflects where we have come as a company since
our inception in 1998 as well as our dedication to advancing targeted pain
management", said Dr. Dan Carr, Chief Executive Officer of Javelin. "We have a
very promising pipeline of pain relief products that rely upon well known
compounds with proven safety and efficacy. By the close of 2005 we expect to
file a marketing authorization application (MAA) for Dyloject(TM), an injectable
form of diclofenac. Our Rylomine(TM) (intranasal morphine), and PMI-150
(intranasal ketamine) product candidates likewise target acute
moderate-to-severe pain, including post-operative pain, orthopedic injury pain,
trauma pain and burn pain".
Upon the reincorporation, each outstanding share of Intrac common stock was
automatically exchanged for one share of Javelin common stock. Javelin's stock
transfer agent will be sending a Letter of Transmittal to all record holders to
enable them to exchange their Intrac stock certificates for Javelin stock
certificates.
ABOUT JAVELIN PHARMACEUTICALS
Javelin Pharmaceuticals is a specialty pharmaceutical company, applying
innovative proprietary technologies to develop new drugs and improved
formulations of existing drugs to target unmet and underserved medical needs in
the pain management market. For additional information please visit the website,
www.javelinpharmaceuticals.com or www.idds.com.
***
This news release contains forward-looking statements. Such statements are valid
only as of today, and we disclaim any obligation to update this information.
These statements are subject to known and unknown risks and uncertainties that
may cause actual future experience and results to differ materially from the
statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve
a high degree of risk. Factors that might cause such a material difference
include, among others, uncertainties related to the ability to attract and
retain partners for our technologies, the identification of lead compounds, the
successful preclinical development thereof, the completion of clinical trials,
the FDA review process and other governmental regulation, our ability to obtain
working capital, our ability to successfully develop and commercialize drug
candidates, and competition from other pharmaceutical companies.
INVESTOR CONTACT: MEDIA CONTACT:
The Investor Relations Group The Investor Relations Group
Christie Mazurek / Ross D'Eredita Janet Vasquez
(212) 825-3210 (212) 825-3210
Javelin Pharmaceuticals, Inc.
June Gregg
(212) 554-4550
2

EX - 99 7 exh99 _ 1 . txt EXH 99 . 1 - PRESS RELEASE - SEPT . 7 , 2005 EXHIBIT 99 . 1 JAVELIN FOR IMMEDIATE RELEASE INTRAC CHANGES NAME TO JAVELIN PHARMACEUTICALS New York , NY , September 7 , 2005 - Today at its annual meeting of shareholders , INTRAC , INC . ( OTC BB : ITRD ) changed its name to Javelin Pharmaceuticals , Inc . as part of a re incorporation in the State of Delaware . Javelin common stock will trade under the symbol JVPH on the OTC Bulletin Board . The shareholders also elected the management slate of directors and ratified the Omnibus Stock Incentive Plan . This renaming reflects the array of pain management opportunities that the Company plans to pursue as it expands beyond its present boundaries . The new name took effect after receiving shareholder approval and completing regulatory filings . Intrac 's wholly owned subsidiary , Innovative Drug Delivery Systems , Inc . , is now a wholly owned subsidiary of Javelin . " This important strategic step reflects where we have come as a company since our inception in 1998 as well as our dedication to advancing targeted pain management " , said Dr . Dan Carr , Chief Executive Officer of Javelin . " We have a very promising pipeline of pain relief products that rely upon well known compounds with proven safety and efficacy . By the close of 2005 we expect to file a marketing authorization application ( MAA ) for Dyloject ( TM ) , an injectable form of diclofenac . Our Rylomine ( TM ) ( intranasal morphine ) , and PMI - 150 ( intranasal ketamine ) product candidates likewise target acute moderate - to - severe pain , including post - operative pain , orthopedic injury pain , trauma pain and burn pain " . Upon the re incorporation , each outstanding share of Intrac common stock was automatically exchanged for one share of Javelin common stock . Javelin 's stock transfer agent will be sending a Letter of Transmittal to all record holders to enable them to exchange their Intrac stock certificates for Javelin stock certificates . ABOUT JAVELIN PHARMACEUTICALS Javelin Pharmaceuticals is a specialty pharmaceutical company , applying innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market . For additional information please visit the website , www.javelinpharmaceuticals.com or www.idds.com . *** This news release contains forward - looking statements . Such statements are valid only as of today , and we disclaim any obligation to update this information . These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made . These statements are based on our current beliefs and expectations as to such future outcomes . Drug discovery and development involve a high degree of risk . Factors that might cause such a material difference include , among others , uncertainties related to the ability to attract and retain partners for our technologies , the identification of lead compounds , the successful preclinical development thereof , the completion of clinical trials , the FDA review process and other governmental regulation , our ability to obtain working capital , our ability to successfully develop and commercialize drug candidates , and competition from other pharmaceutical companies . INVESTOR CONTACT : MEDIA CONTACT : The Investor Relations Group The Investor Relations Group Christie Mazurek / Ross D' Eredita Janet Vasquez ( 212 ) 825 - 3210 ( 212 ) 825 - 3210 Javelin Pharmaceuticals , Inc . June Gregg ( 212 ) 554 - 4550 2